Article
Cell Biology
Zhaoze Guo, Han Zhang, Yiming Fu, Junjie Kuang, Bei Zhao, LanFang Zhang, Jie Lin, Shuhui Lin, Dehua Wu, Guozhu Xie
Summary: Cancer-associated fibroblasts (CAFs) are the most common stromal cells in breast cancer, and they play a role in disease progression and chemoresistance. This study found that CAF-derived conditioned media can promote breast cancer cell growth and radioresistance. The secretion of interleukin 6 (IL-6) by CAFs activates the STAT3 signaling pathway, leading to the growth and radioresistance of breast cancer cells. Inhibition of STAT3 or neutralizing IL-6 can block the effects induced by CAFs. In mouse models, the IL-6 receptor monoclonal antibody tocilizumab can reverse CAF-induced growth and radioresistance. Additionally, poor response to radiotherapy in breast cancer is associated with the expression of IL-6 and p-STAT3. These findings highlight the importance of the IL-6/STAT3 signaling pathway as a potential therapeutic target in breast cancer radiotherapy.
CELL DEATH DISCOVERY
(2023)
Article
Multidisciplinary Sciences
Pauliina M. Munne, Lahja Martikainen, Iiris Raty, Kia Bertula, Nonappa, Janika Ruuska, Hanna Ala-Hongisto, Aino Peura, Babette Hollmann, Lilya Euro, Kerim Yavuz, Linda Patrikainen, Maria Salmela, Juho Pokki, Mikko Kivento, Juho Vaananen, Tomi Suomi, Liina Nevalaita, Minna Mutka, Panu Kovanen, Marjut Leidenius, Tuomo Meretoja, Katja Hukkinen, Outi Monni, Jeroen Pouwels, Biswajyoti Sahu, Johanna Mattson, Heikki Joensuu, Paivi Heikkila, Laura L. Elo, Ciara Metcalfe, Melissa R. Junttila, Olli Ikkala, Juha Klefstrom
Summary: Researchers found that matrix stiffness regulates ERα expression via stress-mediated p38 activation and H3K27me3-mediated epigenetic regulation, revealing a crucial mechanobiological component in hormonal signaling in breast tissue.
NATURE COMMUNICATIONS
(2021)
Article
Biochemistry & Molecular Biology
Zao-zao Zheng, Lin Xia, Guo-sheng Hu, Jun-yi Liu, Ya-hong Hu, Yu-jie Chen, Jia-yin Peng, Wen-juan Zhang, Wen Liu
Summary: This study uncovers the critical role of a super-enhancer-associated positive feedback loop constituting BRD4/ERα-RET-ERα in ERα-positive breast cancer and suggests that targeting components in this loop would provide a new therapeutic avenue for treating ERα-positive breast cancer in the clinic.
NUCLEIC ACIDS RESEARCH
(2022)
Article
Multidisciplinary Sciences
Jake June-Koo Lee, Youngsook Lucy Jung, Taek-Chin Cheong, Jose Espejo Valle-Inclan, Chong Chu, Doga C. Gulhan, Viktor Ljungstrom, Hu Jin, Vinayak V. Viswanadham, Emma V. Watson, Isidro Cortes-Ciriano, Stephen J. Elledge, Roberto Chiarle, David Pellman, Peter J. Park
Summary: This study reveals that focal copy-number amplifications in breast cancer often originate from a mechanism called translocation-bridge amplification, involving inter-chromosomal translocations leading to dicentric chromosome bridge formation and breakage. The model explains the amplifications of key oncogenes and suggests a role of estrogen in generating the initial translocations in breast cancer.
Article
Multidisciplinary Sciences
Xu Li, Shu Zhuo, Ting Zhuang, Yong Suk Cho, Guojin Wu, Yuchen Liu, Kun Mu, Kai Zhang, Peng Su, Yingzi Yang, Cheng Cheng Zhang, Jian Zhu, Jin Jiang
Summary: Hippo signaling restricts tissue growth by inhibiting YAP, which also functions as a tumor suppressor in ER+ breast cancer by interfering with the TEAD-ERα signaling axis.
NATURE COMMUNICATIONS
(2022)
Article
Immunology
Xiaolei Liu, Li Li, Qian Wang, Fengchao Jiang, Pei Zhang, Fei Guo, Hongjun Liu, Jian Huang
Summary: A new humanized anti-IL-6 mAb HZ-0408b with potent binding and neutralizing activity to human IL-6 has been developed. It showed a high species specificity and lower cross-reactivity compared to other anti-IL-6 mAbs. HZ-0408b exhibited a stronger inhibitory effect on IL-6 signaling and effectively reduced joint swelling and plasma CRP levels in a monkey CIA model.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Multidisciplinary Sciences
Eric H. Bent, Luis R. Millan-Barea, Iris Zhuang, Daniel R. Goulet, Julia Frose, Michael T. Hemann
Summary: In a mouse model of BCR-ABL(+) B-cell acute lymphoblastic leukemia, chemotherapy-induced anti-cancer immunity is suppressed by the tumor microenvironment through production of cytokine IL-6. IL-6 inhibits the efficacy of immunotherapy and promotes resistance to doxorubicin, impacting CD8(+) T-cell-mediated anti-cancer responses.
NATURE COMMUNICATIONS
(2021)
Article
Oncology
Melanie Royce, Christy L. Osgood, Anup K. Amatya, Mallorie H. Fiero, C. J. George Chang, Tiffany K. Ricks, Krithika A. Shetty, Jeffrey Kraft, Junshan Qiu, Pengfei Song, Rosane Charlab, Jingyu Yu, Kathryn E. King, Anshu Rastogi, Brian Janelsins, Wendy C. Weinberg, Kathleen Clouse, Vicky Borders-Hemphill, Lindsey Brown, Candace Gomez-Broughton, Zhong Li, Thuy Thanh Nguyen, Zhihao Qiu, Anh-Thy Ly, Suyoung Chang, Tingting Gao, Chi-Ming Tu, Bellinda King-Kallimanis, William F. Pierce, Kelly Chiang, Clara Lee, Kirsten B. Goldberg, John K. Leighton, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani
Summary: Margetuximab-cmkb in combination with chemotherapy was granted regular FDA approval for the treatment of HER2-positive metastatic breast cancer patients who have received two or more prior anti-HER2 regimens. The SOPHIA study demonstrated that margetuximab had a longer median progression-free survival compared to trastuzumab when both were combined with chemotherapy. Infusion-related reactions were reported as important safety signals associated with margetuximab plus chemotherapy.
CLINICAL CANCER RESEARCH
(2022)
Review
Oncology
Juan Chen, Yanghui Wei, Weiqin Yang, Qingnan Huang, Yong Chen, Kai Zeng, Jiawei Chen
Summary: Breast cancer is a leading cause of female mortality, and IL-6 plays a crucial role in its regulation. Recent studies have shown promising outcomes for breast cancer treatment through combination therapy of IL-6 inhibitory antibodies with other drugs.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Tomohiro Tanaka, Tomokazu Ohishi, Teizo Asano, Junko Takei, Ren Nanamiya, Hideki Hosono, Masato Sano, Hiroyuki Harada, Manabu Kawada, Mika K. Kaneko, Yukinari Kato
Summary: The monoclonal antibody TrMab-6 demonstrated strong in vitro antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities against CHO/TROP2 and three breast cancer cell lines, and significantly reduced tumor growth in mouse xenograft models, suggesting its promising potential as a treatment option for TROP2-expressing breast cancers.
Article
Oncology
Gang Liu, Xiang-Ting Chen, Hao Zhang, Xin Chen
Summary: This study investigated the relationship between changes in peripheral blood VEGF, IL-5, IL-6, IL-8, and IL-17 concentrations in breast cancer patients and their significance in breast cancer staging and invasive metastasis. The results showed that IL-6, IL-17, and VEGF were strongly associated with breast cancer development and could be used as reference indicators for diagnosis and postoperative follow-up.
FRONTIERS IN ONCOLOGY
(2022)
Review
Immunology
Nicola Potere, Alberto Batticciotto, Alessandra Vecchie, Ettore Porreca, Antonella Cappelli, Antonio Abbate, Francesco Dentali, Aldo Bonaventura
Summary: IL-6 is a key pro-inflammatory cytokine in COVID-19 patients, particularly in those with severe disease. Pharmacological blockade of the IL-6 signaling pathway has shown promising results in improving outcomes, especially when administered early in the disease course. Further research is needed to better understand the role of IL-6 in different COVID-19 phenotypes and identify patient subgroups that may benefit the most from IL-6 pathway inhibition.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY
(2021)
Review
Biochemistry & Molecular Biology
Marzia Bruna Gariboldi, Emanuela Marras, Nicole Ferrario, Veronica Vivona, Pamela Prini, Francesca Vignati, Gianpaolo Perletti
Summary: Edible/medicinal mushrooms have gained attention in both Asian and European countries for their health and nutritional benefits. They have been found to have various pharmacological activities, including anticancer effects on breast cancer cells. This article reviews the mushrooms that show antineoplastic activity, highlights their bioactive compounds and mechanisms of action, and discusses the relationship between dietary consumption of mushrooms and breast cancer risk as well as clinical studies on the effects of fungal extracts on breast cancer patients.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Oncology
Mona Pourjafar, Massoud Saidijam, Michaela Miehe, Rezvan Najafi, Meysam Soleimani, Edzard Spillner
Summary: Breast cancer (BC) treatment can be challenging due to tumor heterogeneity. In this study, we developed a new bispecific antibody (bsAb) targeting the most common BC cell surface proteins (SPs). This bsAb demonstrated high specificity for its targets and effectively reduced the proliferation and migration of BC cells. Our findings suggest that bsAbs could be a promising targeted therapy for improving the efficacy of BC treatment.
JOURNAL OF IMMUNOTHERAPY
(2023)
Article
Immunology
Jean-Francois Rossi, Hao-Chun Chiang, Zhao-Yang Lu, Kalle Levon, Frits van Rhee, Karan Kanhai, David C. Fajgenbaum, Bernard Klein
Summary: Standard doses of anti-IL-6 therapy were found to inadequately inhibit IL-6 signaling in patients with COVID-19 or iMCD, resulting in partial inhibition of CRP production. In situations of high IL-6 production, repeated administration of anti-IL-6 therapy was shown to effectively inhibit IL-6 activity.
FRONTIERS IN IMMUNOLOGY
(2022)
